Loading clinical trials...

Survey on PD Patients With Depressive Symptoms | Clinical Trials | Clareo Health

COMPLETED

Survey on PD Patients With Depressive Symptoms

BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)

NCT00614575•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy. i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•\*\*PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance.

Exclusion Criteria

•PD patients with the past history of suicidal attempt, suicidal ideation or tendency
•PD patients with suicidal ideation
•PD patients with the past history of suicidal tendency

Locations (238)

Boehringer Ingelheim Investigational Site

Akashi, Japan

Boehringer Ingelheim Investigational Site 1

Akita, Japan

Boehringer Ingelheim Investigational Site 2

Akita, Japan

Boehringer Ingelheim Investigational Site

Asahikawa, Japan

Boehringer Ingelheim Investigational Site

Ashikaga, Japan

Boehringer Ingelheim Investigational Site

Awaji, Japan

Boehringer Ingelheim Investigational Site

Chitose, Japan

Boehringer Ingelheim Investigational Site

Chūō, Japan

Boehringer Ingelheim Investigational Site 1

Fuchū, Japan

Boehringer Ingelheim Investigational Site 2

Fuchū, Japan

Key Dates

Start Date

January 1, 2007

Primary Completion Date

August 1, 2009

Last Updated

August 6, 2014

Enrollment

1,089

ACTUAL participants

Conditions

Parkinson Disease

Sponsors

Lead Sponsor

Boehringer Ingelheim

Related Studies

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions